Sugi Predict

Sugi Predict / Targets / FOLR1

FOLR1

Folate receptor alpha · P15328 · FOLR1 on Sugi Atlas →

7,605 patent compounds predicted against FOLR1, 4,707 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3161181 SCHEMBL3161181 0.73 17/20
SCHEMBL3162474 SCHEMBL3162474 1.00 16/20
SCHEMBL3162499 SCHEMBL3162499 1.00 16/20
SCHEMBL3161202 SCHEMBL3161202 0.78 16/20
SCHEMBL1605562 SCHEMBL1605562 0.56 16/20
SCHEMBL1604409 SCHEMBL1604409 0.54 16/20
SCHEMBL1605557 SCHEMBL1605557 0.53 16/20
SCHEMBL1604402 SCHEMBL1604402 0.79 15/20
SCHEMBL1605463 SCHEMBL1605463 0.78 15/20
SCHEMBL1604607 SCHEMBL1604607 0.78 15/20
SCHEMBL1604476 SCHEMBL1604476 0.73 15/20
SCHEMBL1604480 SCHEMBL1604480 0.73 15/20
SCHEMBL1604603 SCHEMBL1604603 0.72 15/20
SCHEMBL1604705 SCHEMBL1604705 0.72 15/20
SCHEMBL3159760 SCHEMBL3159760 0.72 15/20
SCHEMBL1604885 SCHEMBL1604885 0.69 15/20
SCHEMBL1604587 SCHEMBL1604587 0.68 15/20
SCHEMBL1604592 SCHEMBL1604592 0.68 15/20
SCHEMBL1604597 SCHEMBL1604597 0.64 15/20
SCHEMBL1604546 SCHEMBL1604546 0.58 15/20

Clinical trials — most relevant to FOLR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer PHASE3ACTIVE_NOT_RECRUITING
A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer PHASE3UNKNOWN
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression PHASE3COMPLETED
How Precision Diets, Through Gut Bacteria, Affect Anemia in Nepalese Adolescent PHASE3NOT_YET_RECRUITING
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer. PHASE2RECRUITING
Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma PHASE2COMPLETED
A Placebo-controlled Trial of Folinic Acid in Children With ASD PHASE2RECRUITING
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma PHASE2COMPLETED
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer PHASE2RECRUITING
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer PHASE2ACTIVE_NOT_RECRUITING
Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer PHASE2COMPLETED
Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02) PHASE2COMPLETED
Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study PHASE2UNKNOWN
10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers PHASE2COMPLETED
Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer PHASE2COMPLETED
Intraoperative Imaging of Pulmonary Nodules by OTL38 PHASE1COMPLETED
[18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging PHASE1COMPLETED
Study of EC0225 for the Treatment of Refractory or Metastatic Tumors PHASE1COMPLETED
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors PHASE1COMPLETED
Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer PHASE1COMPLETED
The Development of Human Immunologic Assays Specific to Folate Receptor Antigen nanUNKNOWN
Measurement of the Folate Receptor in Blood nanCOMPLETED
Clinical Antenatal Randomised Study to CharactErise Key Roles of TetrahydroFOLate in HyperTensive Pregnancies nanRECRUITING
PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer nanUNKNOWN
DHFR 19 bp Deletion Polymorphism and Folic Acid Utilization nanCOMPLETED
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer nanUNKNOWN
Influence of Iron and Foliate Transporters on Bioavailability of These Micronutrients in the Organism nanCOMPLETED
FR in Stored Plasma nanCOMPLETED
Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524 nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a FOLR1 binder may also engage these)

ProteinNameSimilarity
P41439 — 1.000 P41439 →
P35846 — 1.000 P35846 →
P02702 — 1.000 P02702 →
Q05685 — 1.000 Q05685 →
FOLR2 Folate receptor beta 0.996 landscape →
F1M928 — 0.994 F1M928 →
A6ND01 — 0.992 A6ND01 →
Q9EQF4 — 0.989 Q9EQF4 →
P02752 — 0.987 P02752 →
P86009 — 0.979 P86009 →
Q9TTK6 — 0.977 Q9TTK6 →
O70423 — 0.977 O70423 →
A2A863 — 0.977 A2A863 →
Q5T197 — 0.977 Q5T197 →
Q9R1Q9 — 0.977 Q9R1Q9 →
Q8N158 — 0.976 Q8N158 →
Q3U435 — 0.976 Q3U435 →
Q5XHC5 — 0.976 Q5XHC5 →
Q8JZQ5 — 0.976 Q8JZQ5 →
PRF1 Perforin-1 0.975 landscape →
Q9DBX3 — 0.975 Q9DBX3 →
Q9UK23 — 0.975 Q9UK23 →
A6QQ07 — 0.975 A6QQ07 →
P78333 — 0.975 P78333 →
INSRR Insulin receptor-related protein 0.975 landscape →
F1QCC6 — 0.974 F1QCC6 →
P26011 — 0.974 P26011 →
Q3V5L5 — 0.974 Q3V5L5 →
Q9EPR2 — 0.974 Q9EPR2 →
Q5M936 — 0.974 Q5M936 →